TIME MAY 2, 2019- 2nd İstanbul Immunohematology Summit
08:15-08:30 Opening Ceremony: Muhlis Cem Ar (TSH General Secretary)
 08:30-09:30 Chair: Osman İlhan (Ankara University, Turkey), Reyhan Küçükkaya (Turkey)
08:30-09:00 Innate Immunity: Günnur Deniz (İstanbul University, Turkey)
09:00-09:30 Acquired Immunity: Safa Barış (Marmara University, Turkey)
09:30-09:45  Coffee Break
09:45-10:45  Chair: Yıldız Camcıoğlu (Istanbul University, Turkey)
Primary Immune Deficiencies: Elif Aydıner Karakoç (Marmara University, Turkey)
10:45-11:00  Coffee Break
11:00-12:00  Chair: Tevfik Akoğlu (Marmara University, Turkey)
 Current Immunotherapies: Meral Beksaç (Ankara University, Turkey)
12:00-13:00  Lunch
TSH/EBMT CTIWP Joint CAR-T Cell Symposium
Chair: Christian Chabannon (Marseille University, France), Güner Hayri Özsan (Dokuz Eylül University, Turkey)
13:00-13:30 Regulatory Issues and Standards for CAR-T Cell Administration: Christian Chabannon (Marseille University, France)
13:30-14:00 Biology of CAR-T Cells: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain)
14:00-14:30 Cell Procurement for CAR-T Cell Manufacturing:Christian Chabannon (Marseille University, France)
14:30-15:00  Coffee Break
Chair: Ibrahim Yakoub Agha (Lille University Hospital, France), Mutlu Arat (Florence Nightingale, Turkey)
15:00-15:30 Clinical Results of CAR-T Cell in Acute Lymphoblastic Leukemia: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain)
15:30-16:00 Clinical Results of CAR-T Cell in Non Hodgkin Lymphoma: Ibrahim Yakoub Agha (Lille University Hospital, France)
16:00-16:30  Coffee Break
Chair: Alvaro Urbano Ispizua (Josep Carreras Leukaemia Research Institue, Spain), Muhit Özcan (Ankara University, Turkey)
16:30-17:00 Clinical Results of CAR-T Cell in Multiple Myeloma: Ibrahim Yakoub Agha (Lille University Hospital, France)
17:00-17:30 Qualification of the EBMT Registry by the EMA for CAR-T Cell: Jürgen Kuball (University Medical Center Utrecht, Holland)

 

TIME MAY 3, 2019
08:30-10:00 ACUTE MYELOID LEUKEMIA
Scientific Chair: Gert Ossenkoppele (VU University Medical Center , The Netherlands), İnci Alacacıoğlu (Dokuz Eylül University, Turkey)
AML Treatment Beyond 3+7: Hartmut Dohner (University Hospital Ulm, Germany)
 The Emerging Role of MRD in AML: Gert Ossenkoppele (VU University Medical Center, The Netherlands)
Immunotherapy in AML: AlloSCT Towards CAR-T Cell Therapy: Marion Subklewe (Ludwig Maximilian University, Germany)
10:00-10:30 COFFEE BREAK
10:30-12:00 ACUTE LYMPHOBLASTIC LEUKEMIA
Scientific Chair: Dieter Hoelzer (University of Frankfurt, Germany), Teoman Soysal (Istanbul University, Turkey)
 Progress in T-lineage ALL/TLBL: Renato Bassan ( Ospedale dell’ Angelo e Ss. Giovanni e Paolo, Italy)
 B-Lineage ALL, Targeted Therapy: Dieter Hoelzer (University of Frankfurt, Germany)
 Current Status on CAR-T Cells : Álvaro Urbano-Ispizua (Josep Carreras Leukaemia Research Institue, Spain)
12:00-14:00 SATELLITE SYMPOSIUM  amgen logo ile ilgili görsel sonucu / LUNCH

Scientific Chair: Meral Beksaç (Ankara University, Turkey)
Evolving Landscape of Relapsed Multiple Myeloma Treatment with Carfilzomib: Thierry Facon (Lille University Hospital, France)

14:00-15:30 CHRONIC MYELOID LEUKEMIA
Scientific Chair: Jane Apperley (Imperial College London, UK), Düzgün Özatlı (Ondokuz Mayıs University, Turkey)
 
Choosing First and Second Line Therapies in the Era of Generic TKI : Tomasz Sacha (Jagiellonian University, Poland)
 
Role of Molecular Monitoring in CML: Jane Apperley (Imperial College London, UK)
Considerations for Discontinuing Therapy : Francois Mahon  (Institut Bergonié, France)
15:30-16:00 COFFEE BREAK
16:00-17:00 ORAL PRESENTATIONS
17:00-17:30 COFFEE BREAK
17:30-18:30 MULTIPLE MYELOMA
Scientific Chair: Pieter Sonneveld (Erasmus MC, The Netherlands), Ömür Gökmen Sevindik (Medipol University, Turkey)
Modern Approaches in Multiple Myeloma Treatment: Pieter Sonneveld (Erasmus MC, The Netherlands)
Treatment of Relaps /Refractory Multiple Myeloma: Thierry Facon (Lille University Hospital, France)

 

TIME MAY 4, 2019
08:30-10:00 CHRONIC LYMPHOCYTIC LEUKEMIA
Scientific Chair: Anna Schuh (Oxford Molecular Diagnostics Centre, UK), Fatih Demirkan (Dokuz Eylül University, Turkey)
Clinical Applications of Prognostic Markers in Chronic Lymphocytic Leukemia: Piers Patten (King’s College Hospital, London)
Frontline Therapy of Chronic Lymphocytic Leukemia: Anna Schuh (Oxford Molecular Diagnostics Centre, UK)
Treatment of Relapsed Chronic Lymphocytic Leukemia: Anne Quinquenel (Centre Hospitalier Universitaire de Reims, France)
10:00-10:30 COFFEE BREAK
10:30-12:00 HODGKIN LYMPHOMA
Scientific Chair: Andreas Engert (University Hospital of Cologne, Germany), Ahmet Muzaffer Demir (Trakya University, Turkey)
 1st line treatment of HL : Andreas Engert (University Hospital of Cologne, Germany) 
Nodular Lymphocyte Predominant Hodgkin Lymphoma: Dennis Eichenauer (University of Cologne, Germany)
Recent Developments in Relapsed/Refractory Classical Hodgkin Lymphoma: Paul Bröckelmann (University of Cologne, Germany)
12:00-14:00 LUNCH
SATELLITE SYMPOSIUM
(12:15-13:15)
A New Dimension in Treatment of Relapsed and Refractory Multiple Myeloma: Darzalex Experiences
Scientific Chair: Yıldız Aydın (İstanbul University, Turkey)
Speakers: Sevgi Beşışık (İstanbul University, Turkey), Ant Uzay (Acıbadem University, Turkey)
14:00-15:30 INDOLENT LYMPHOMAS
Scientific Chair: Eva Kimby (Karolinska Institute, Sweden), Burhan Ferhanoğlu (Koç University, Turkey)
Novelties in the Management of Marginal Zone Lymphoma: Catherine Thieblemont (Hospital Saint Louis, France)
Follicular Lymphoma – Focus on Therapy: Eva Kimby (Karolinska Institute, Sweden)
Cellular Therapies for Follicular Lymphoma: Koen Van Besien (Presbyterian Hospital, USA)
15:30-16:00 COFFEE BREAK
16:00-17:30 AGGRESSIVE LYMPHOMAS
Scientific Chair: Martin Dreyling (Klinikum der Universität LMU München, Germany), Olga Meltem Akay (Koç University, Turkey)
Current Standards in First Line DLBCL: Andrew Davies (University of Southampton, UK)
Molecular Subtypes of DLBCL and Clinical Implications: Björn Chapuy (University Medical Center and Comprehensive Cancer Center, Germany)
Mantle Cell Lymphoma: Current Standards and Future Study Concepts: Martin Dreyling (Klinikum der Universität LMU München, Germany)